Bap1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study

HIGHLIGHTS

• who: Amber Louw BSc M.B.B.S. from the Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia School of Medical and Health Sciences, Edith Cowan University, Perth, Australia have published the article: BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study, in the Journal: (JOURNAL)
• what: The aim of this study was to investigate whether patients with PM with tumors harboring BAP1 loss as determined by IHC have improved survival to a firstline chemotherapeutic regimen of platinum . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.